FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/12/060768 [Registered on: 26/12/2023] Trial Registered Prospectively
Last Modified On: 22/09/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Mixed Method Implementation Research]  
Study Design  Other 
Public Title of Study   Trial on feeding for Low birth and premature babies 
Scientific Title of Study   Low Birthweight and Preterm Infant Feeding Trial and Supportive Care Package (LIFT-UP) 
Trial Acronym  LIFT-UP 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Roopa M Bellad 
Designation  Professor Paediatrics 
Affiliation  J N Medical College KAHER Belagavi  
Address  Department of Paediatrics, J N Medical College, KLE Academy of Higher Education and Research, Nehru Nagar Belagavi

Belgaum
KARNATAKA
590010
India 
Phone  9448113403  
Fax  918312472891  
Email  belladroopa5@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Roopa M Bellad 
Designation  Professor Paediatrics 
Affiliation  J N Medical College KAHER Belagavi  
Address  Department of Paediatrics, J N Medical College, KLE Academy of Higher Education and Research, Nehru Nagar Belagavi

Belgaum
KARNATAKA
590010
India 
Phone  9448113403  
Fax  918312472891  
Email  belladroopa5@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Roopa M Bellad 
Designation  Professor Paediatrics 
Affiliation  J N Medical College KAHER Belagavi  
Address  Department of Paediatrics, J N Medical College, KLE Academy of Higher Education and Research, Nehru Nagar Belagavi

Belgaum
KARNATAKA
590010
India 
Phone  9448113403  
Fax  918312472891  
Email  belladroopa5@gmail.com  
 
Source of Monetary or Material Support  
Bill and Melinda Gates Foundation  
 
Primary Sponsor  
Name  Bill and Melinda Gates Foundation  
Address  440 5th Ave N. Seattle, WA 98109 USA 
Type of Sponsor  Other [Charitable Foundation] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India
Malawi
Tanzania  
Sites of Study
Modification(s)  
No of Sites = 5  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Durugappa H  Ballari Medical College and Research Centre, Ballari  Department of Paediatrics, First Floor, BMCRC Hospital, Ballari Medical College and Research Centre, Vijaya Nagar, Cantonment, Ballari, 583104
Bellary
KARNATAKA 
9740090169

drdurgappaudbal1012@gmail.com 
Dr Gururprasad G  Bapuji Child Health Institute and Research Center affiliated to JJM College, Davangere  Bapuji Child Health Institute and Research Center, Department of Neonatology, First floor, 2nd Main, Bapuji Hospital Road, MCC B Block, Davangere - 577004
Davanagere
KARNATAKA 
9844065889

dr_g_gp@yahoo.com 
Dr Shivangouda Joladarashi  Gadag Institute of Medical Sciences, Gadag  Department of Paediatrics, Gadag Institute of Medical Sciences, SH 6, Malasamudra, Gadag. PIN- 582103
Gadag
KARNATAKA 
9663259138

shivanagoudajoladarasi@gmail.com 
Dr Swapna Lingaldinna  Institute of Child Health, Niloufer Hospital, affiliated to Osmania Medical College, Hyderabad  Institute of Child Health – Niloufer Hospital, 11-4-721, Niloufer Hospital Rd, Red Hills, Lakdikapul, Hyderabad, Telangana, PIN 500004
Hyderabad
TELANGANA 
9848082441

drswapnalingaldinna@gmail.com 
Dr Roopa M Bellad   KLES Dr Prabhakar Kore Hospital and Medical Research Centre Belgaum   Department of Paediatrics J N Medical College and Womens and Childrens Health Research Unit Wing, First Floor, KLE Academy of Higher Education and Research Nehru Nagar 590010 Belgaum
Belgaum
KARNATAKA 
9448113403

belladroopa5@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 5  
Name of Committee  Approval Status 
Ballari Medical College and Research Centre, Ballari Institutional Ethics Committee  Approved 
Institutional Ethics Committee Gadag Institute of Medical Sciences, Gadag  Approved 
Institutional Ethics Committee JJM Medical College Davangere   Approved 
Institutional Ethics Committee of KLE Academy of Higher Education and Research  Approved 
Institutional Ethics Committee of Osmania Medical College  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: P071||Other low birth weight newborn, (2) ICD-10 Condition: P073||Preterm [premature] newborn [other],  
 
Intervention / Comparator Agent
Modification(s)  
Type  Name  Details 
Comparator Agent  Control group (No fortification)  Dosage: Standardized volume targets and trajectories protocol Frequency: Every infant feed Administration: Oral Duration: For a minimum duration of 21 days post-randomization. After the minimum duration of 21 days post randomization, hospitalized infants should continue to receive volume-targeted feeding without HMF for as long as they are receiving expressed breast milk. Once infants have transitioned to full, direct breastfeeding in preparation for discharge or being discharged per clinician discretion, they will stop adhering to the volume targets. 
Intervention  Fortification of human milk with Lactodex  Dosage: Powdered HMF will be added to the cup with the human milk (either MOM or PDHM if available) per the manufacturers specifications-One gram of HMF per 25 mL of human milk Frequency: Every infant feed Administration: Oral Duration: For a minimum duration of 21 days post-randomization. After the minimum duration of 21 days post randomization, hospitalized infants should continue to receive volume-targeted feeding with HMF for as long as they are receiving expressed breast milk. Once infants have transitioned to full, direct breastfeeding in preparation for discharge or being discharged per clinician discretion, they will stop adhering to the volume targets and infants in the intervention group will stop receiving fortified human milk. 
 
Inclusion Criteria  
Age From  0.00 Day(s)
Age To  70.00 Year(s)
Gender  Both 
Details  For RCT
1. Very LBW (<1.5 kg) or very preterm (<32 weeks) admitted to NICU at study facility <24 hours after birth for in-born infants and up to 48 hours for out-born (timing of admission may be extended to meet sample size goals)
2. Mother and infant alive during screening
3. Mother age 18+ years (India and Tanzania) or 16-18 and married (Malawi only)
4. Lives within catchment areas of the facility (50km)
5. Infant receiving at least 60 mL/kg/day of human milk

For Qualitative Research
1. Stakeholders with some familiarity with or expertise regarding the use of probiotics for very preterm infants within the study country
2. Key stakeholder consents for him/herself 
 
ExclusionCriteria 
Details  For RCT
1. Lives outside the defined catchment area
2. Congenital abnormalities or acquired conditions that interfere with feeding or placement of NG/OG tube [cleft lip/palate, Toxoplasmosis, other agents, rubella, cytomegalovirus, and herpes (TORCH), Trisomy 21, Congenital cardiac defect, neural tube defect, gastrointestinal (GI) tract anomalies, hydrocephalus, NEC]
3. Severe birth asphyxia
4. Critically ill (i.e. not on enteral feeds)
5. Unknown date of birth and unknown gestational age

For Qualitative Research
N/A 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Centralized 
Blinding/Masking   Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
For RCT
Mean (Standard Deviation [SD]) Length-for-age Z score (LAZ) at 3 months

For Qualitative Research
1. Perceived acceptability & utility of probiotic interventions
2. Feasibility of implementation of probiotics 
At 3 months of chronological age 
 
Secondary Outcome
Modification(s)  
Outcome  TimePoints 
For RCT
Mean (SD) length of stay from randomization to facility discharge
Feeding intolerance between randomization & facility discharge (yes/no)
Weight growth velocity (attaining 15 g/kg/d) from randomization to facility discharge (yes/no)
Mean (SD) weight growth velocity between randomization & facility discharge
Mean (SD) length gain (mm per wk) from randomization to facility discharge
Mean (SD) head circumference gain (mm per wk) from randomization to facility discharge
NEC from randomization to facility discharge (yes/no)
Sepsis/ possible serious bacterial infection (PSBI) from randomization to facility discharge (yes/no)
Infant mortality from randomization to facility discharge (yes/no) 
Randomization to facility discharge 
For RCT
Birthweight regain by 2 weeks (yes/no) 
2 weeks of age 
For RCT
Mean (SD) weight growth velocity from randomization to 4 weeks
Neonatal mortality from randomization to 4 weeks (yes/no)
Sepsis/PSBI from randomization to 4 weeks (yes/no) 
4 weeks of age 
For RCT
Mean (SD) weight-for-age Z score (WAZ) at 3 months
Mean (SD) weight-for-length Z score (WLZ) at 3 months
Mean (SD) head circumference-for-age Z score (HcAZ)
Change in WAZ between randomization & 3 months
Change in LAZ between randomization & 3 months 
3 months of age 
For Qualitative Research
Facilitators/benefits & barriers/risk of introducing probiotics
Existing use of probiotics or similar interventions & successes/failures
Regulatory & administrative requirements for new intervention use & associated policy change
Risks mitigation
Supply chain & impact of availability of electricity, transportation issues, & seasonality
Guideline review processes
Required infrastructure/support for implementation (e.g., water, sanitation, & hygiene (WASH), policy, guideline changes) 
Over the study period 
 
Target Sample Size   Total Sample Size="1222"
Sample Size from India="601" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   01/01/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  01/01/2024 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="9"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Open to Recruitment 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form
    Response - Clinical Study Report

  3. Who will be able to view these files?
    Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.

  4. For what types of analyses will this data be available?
    Response - To achieve aims in the approved proposal.

  5. By what mechanism will data be made available?
    Response (Others) -  By Email communication to Dr Roopa Bellad (belladroopa5@gmail.com), Dr S M Dahded (drdhadedsm@gmail.com) and Dr Shivaprasad S Goudar (sgoudar@jnmc.edu)

  6. For how long will this data be available start date provided 01-08-2026 and end date provided 31-07-2031?
    Response - Beginning 3 months and ending 5 years following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  

Background

Low birth weight: 20 Million per year globally & nearly 15 million are born preterm (<37 weeks). At higher risk of Morbidity, Mortality, growth deficits, feeding difficulties & neurodevelopmental delays. It accounts for more than 80% of neonatal deaths. â€œWorld Health Assembly set out to reduce LBW by 30% by 2025”. Crucial for promoting LBW or preterm infants’ access to Mother’s Own Milk (MOM)LBW or preterm infants experience unique feeding challenges compared to healthy full-term infants, including but not limited to

a. immature gastrointestinal tract resulting in feeding intolerance,

b. inability to coordinate swallow-breath interface which is important for safe feeding,

c. rapid fatigue during feeds before adequate volume is consumed,

d. inability to feed directly at the breast effectively and efficiently

Lactation support during the first two weeks postpartum is crucial to establish an adequate breast milk supply by helping the mother frequently, effectively, and efficiently remove breast milk from her breasts. Mothers and families of LBW or preterm infants in the NICU face unique psychosocial challenges, including psychological distress, guilt, shame, stress, anxiety, depression, and posttraumatic stress disorder which can impact family care of the LBW or preterm infant. KMC is a high-impact intervention, which can serve to help a mother-infant dyad to start and maintain breastfeeding. It has been proven to reduce the risk of neonatal mortality by 40%. Additionally, expressed breast milk should be safely and hygienically handled, labeled, stored, and fed to the infant in clean, dry, food-grade/BPA-free hard plastic container with a secure lid. Currently, a comprehensive specialized lactation support and management curriculum with attention to the provision of KMC and WASH measures (including trainer’s guide, trainee’s guide, and implementation guidance) targeted specifically to LBW or preterm infants and designed for low-resource settings does not exist.

Human milk (MOM or DHM) does not contain sufficient micro and macronutrients for preterm infants to sustain a growth pattern that matches the final weeks of in utero development. Preterm formula contains additional energy proteins, and other macro- and micronutrients that the very low birthweight/ very preterm infant needs. Therefore, fortification of human milk may be necessary to encourage increased growth rates in preterm infants. It is important to note that in-hospital fortification has not been conclusively demonstrated to improve clinical or neurodevelopmental outcomes. Probiotic supplementation, which may aid in digestion and in illness prevention/management, could be beneficial to LBW or preterm infants as they are already at increased risk of morbidity and mortality. The new WHO Recommendations for care of the preterm or low-birth-weight infant include a conditional recommendation that probiotics may be considered for human milk fed very preterm infants (<32 weeks)

This study directly addresses recommendations and call for research outlined by the WHO:

a. Fortification of human milk may be considered for very LBW (<1500g) or very preterm (<32 week) infants who are fed MOM or DHM (conditional recommendation).

b. Probiotics may be considered for human milk fed very preterm (<32 weeks) infants to reduce NEC, sepsis, and mortality (conditional recommendation).

Study aims, objectives, and hypotheses

a. RCT

Aim: To improve feeding and growth outcomes among very low birthweight (LBW; ≤1.5kg) or very preterm (<32 weeks gestational age) infants admitted to neonatal intensive care units (NICU) in India, Malawi, and Tanzania through fortification of human milk.

Objective: To evaluate (via individually randomized controlled study) the effectiveness of a feasible, advanced feeding and fortification clinical protocol for very LBW or very preterm infants in the NICU consuming human milk (mother’s own milk [MOM] or pasteurized donor human milk [PDHM]) around the time of birth on their clinical outcomes compared to a comparison arm receiving unfortified human milk.

Hypothesis: Very LBW or very preterm infants in the NICU who are fed fortified human milk using a standardized protocol will have better growth outcomes by facility discharge and at 3 months of age, less illness by discharge and decreased mortality by discharge and at one month compared to those who receive unfortified human milk

b. Exploratory Qualitative Research

Aim: To improve feeding and growth outcomes among low birthweight (LBW; <2.5kg) or preterm (<37 weeks gestational age) infants in the neonatal intensive care unit (NICU) in India, Malawi, and Tanzania by exploring stakeholder perspectives regarding the provision of probiotics for very preterm (<32 weeks gestational age) infants in health facilities.

Objective: To determine acceptability and feasibility (via qualitative research) of probiotic use for hospitalized very preterm infants among key stakeholders.

Hypothesis: Key stakeholders believe that introducing probiotics for very preterm infants in the hospital setting in low- and middle-income countries (LMICs) is acceptable and feasible.

Study design 

a. RCT: This is a multi-site, multi-country RCT. Quantitative data will be collected in order to comprehensively address the study objective. In order to facilitate and inform the conduct of study activities, a facility needs assessment will be conducted in each study facility.

Intervention: In-facility fortification of human milk with powdered HMF using a feasible, advanced feeding and fortification clinical protocol Standardized volume targets and trajectories protocol Provision of guideline-driven standard of care (facility-based lactation support/feeding counseling + KMC + WASH package and breast pumps)

Control: No fortification of human milk Standardized volume targets and trajectories protocol Provision of guideline-driven standard of care (facility-based lactation support/feeding counseling + KMC + WASH package and breast pumps)

b. Exploratory Qualitative Research

This is a multi-site, multi-country exploratory qualitative research study. The purpose of the qualitative component is to examine the feasibility and acceptability of probiotic use in hospitalized very preterm infants via IDIs with key stakeholders. The research will be conducted in India, Malawi, and Tanzania, but is not affiliated with specific facilities

Study populationFacility needs assessment (for India study facilities) - All study facilities (not individual-specific)

a. RCT: Very LBW or very preterm infants admitted to the NICU in study facilities who consume human milk, meet eligibility criteria (and their mothers) and were randomized to the intervention / comparison group

b. Exploratory Qualitative Research: Key stakeholders who can provide insight on the feasibility and acceptability of probiotic use in hospitalized very preterm infants. Key stakeholders will include:

i. clinical providers,

ii. hospital leadership,

iii. supply chain experts,

iv. policymakers, Ministry of Health (MoH) officials, etc. with knowledge and expertise in probiotic use for very preterm infants.

Sample size

a. RCT

Of the total sample, 581 will be randomized to the intervention (fortified human milk) and 581 to the control (unfortified human milk). For the mother-infant dyad surveys, we plan to enroll 50% of participants in the India sites and 50% in the African sites (Malawi and Tanzania combined).

b. Exploratory Qualitative Research

The maximum number of key stakeholders who will be interviewed is up to 60 key stakeholders (until saturation is reached). Each country partner will conduct a similar number of IDIs (up to 20).

Study procedures

a. RCT: Randomization

The trial has two study arms:

Intervention: fortification of human milk;

Comparison: no fortification of human milk.

Infants will be randomized individually in a 1:1 fashion to the intervention or comparison arm. Multiple births will be randomized together (i.e., all siblings will be in the same arm) and this will be accounted for in the analysis. Randomization sequences will be generated by study epidemiologists/statisticians using a computer program. Each site will have a set of randomization sequences for their study population to ensure balance of study arms at the site level.

Blinding and bias reduction: During the implementation of the study, data collectors and the analysis team will be blinded to study arm assignments to reduce bias in data collection and analysis. For data analysis, groups will be labeled with a letter (A vs B) to conceal allocation assignment.

b. Exploratory Qualitative Research

Translations and local adaptation of the study tools

All data collection materials used in the study (e.g., consent forms, interview guides) which need translation will be translated into the local language according to established practices (Hindi and Kannada)

IDIs with key stakeholders

IDIs with key stakeholders (N=up to 60) will be conducted by study staff. The goal of the IDIs is to collect essential information about acceptability and feasibility probiotic use for very preterm infants among key stakeholders. Interviews will be held in a safe, private, and quiet location as determined by the study team.

Locations of interviews will meet the following criteria:

• Comfortable for participants where they can speak freely without judgment (i.e. a private location inside the person’s home or their place of work).

• An open - yet private - space of the mutual agreement between the interviewer and participant

Data analysis plan

a. RCT: The analysis will include a combination of descriptive statistics as well as models to look at predictors and relationships. For each infant in the RCT, we will have data on maternal characteristics, prenatal care utilization, delivery variables, infant traits, and health outcomes. Importantly, we will also have observational and self-reported data on the feeding strategies used

b. Exploratory Qualitative Research: A comprehensive, thematic analysis will be conducted by two coders using an in-depth coding approach in Dedoose/NVIVO software to identify key themes related to commensality as well as similarities and differences between the two respondent groups. The two coders will double code at least 10% of the interviews before proceeding to single coding

Data Safety Monitoring Plan

a. RCT: Ariadne Labs team will regularly assess enrollment, outcomes and adverse events to monitor adherence to the protocol and data collection procedures. The team will review data through REDCap application and send queries to the sites using the REDCap system, whereupon site staff will make the necessary corrections to the database. An independent DSMB will be established and convened to assess participant safety and advise on study continuation.

b. Exploratory Qualitative Research: All data collectors will be trained to make respondents comfortable and not share personal data or introduce any bias. Audio files of interviews will be uploaded to a secure data storage system as soon as possible. After the audio file is uploaded to the secure data storage system, it will be permanently deleted from the audio recorder.

 
Close